未知生产厂商
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India. The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest. Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system. The DNA vaccine platform offers minimal biosafety requirements, more improved vaccine stability, and lower cold chain requirements. Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting successful dosing and tolerance. As of August, 2020 the candidate is in Phase II clinical trials.
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India. The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest. Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system. The DNA vaccine platform offers minimal biosafety requirements, more improved vaccine stability, and lower cold chain requirements. Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting successful dosing and tolerance. As of August, 2020 the candidate is in Phase II clinical trials.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
